Table 6.

Prognostic factors for overall survival in the imatinib combined with hepatic resection group (IM+HR) and imatinib combined with radiofrequency ablation or transarterial chemoembolization group (IM+RFA/TACE) after propensity score matching.

Variables	Univariate HR (95% CI)	P	Multivariate HR (95% CI)	P
Sex (male vs. female)	1.077 (0.197–5.902)	0.932
Age (≤60 vs. >60 years)	0.156 (0.025–0.954)	0.044	0.119 (0.017–0.856)	0.035
Primary Sites (stomach vs. others)	1.032 (0.328–8.123)	0.550
Metastatic phase (metachronous vs. synchronous)	0.466 (0.084–2.602)	0.384
Number of Metastases (≤3 vs. >3)	0.199 (0.023–1.709)	0.141
Largest diameter of metastases (≤3 vs. >3 cm)	0.802 (0.162–3.979)	0.781
Extrahepatic metastases (no vs. yes)	0.377 (0.068–2.081)	0.263
IM response before surgical treatment (PR+SD+NA vs. PD)	0.476 (0.095–2.388)	0.367
Status after surgical treatment (NED vs. non-NED)	0.150 (0.017–1.295)	0.084	0.122 (0.013–1.136)	0.065
Therapy (IM+HR vs. IM+RFA/TACE)	0.182 (0.021–1.560)	0.120

HR, hazard ratio.

NA, not applicable; NED, no evidence of disease; PD, progressive disease; PR, partial response; SD, stable disease.